Skip to main content

6 Result(s)

within Cho-Ming Loi Remove this filter

and

  1. No Access

    Article

    Cardiovascular differentiation of imatinib and bosutinib in the rat

    Imatinib and bosutinib were administered to rats for up to 6 months at clinically relevant exposures to investigate the effects on the cardiovascular system. Imatinib treatment resulted in increased volume, wa...

    Jonathan R. Heyen, Wenyue Hu, Joseph Jamieson… in International Journal of Hematology (2013)

  2. No Access

    Article

    A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers

    This study aimed to characterize the primary routes of elimination of the pan-HER tyrosine kinase inhibitor, dacomitinib (PF-00299804), to evaluate the pharmacokinetics of total radioactivity and of dacomitini...

    Carlo L. Bello, Evan Smith, Ana Ruiz-Garcia… in Cancer Chemotherapy and Pharmacology (2013)

  3. No Access

    Article

    Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

    The MEK–mitogen-activated protein kinase (MAPK) signal transduction pathway is involved with numerous cellular processes including cell growth and differentiation. Phosphorylation of MAPK (pMAPK) by MEK result...

    Alan P. Brown, Tage C. G. Carlson, Cho-Ming Loi… in Cancer Chemotherapy and Pharmacology (2007)

  4. No Access

    Article

    Pharmacokinetics of Troglitazone in Patients with Renal Insufficiency

    Objective: The pharmacokinetic profiles of troglitazone and two metabolites were evaluated following a single 400mg oral dose of troglitazone in 20 patients with various degrees of renal function...

    Philip W. Knowlton, Cho-Ming Loi, Artemios B. Vassos… in Clinical Drug Investigation (1999)

  5. No Access

    Article

    Hepatic Drug Metabolism and Aging

    Although there is considerable variation in the effect of age on drug biotransformation, the metabolism of many drugs is impaired in the elderly. Age-related physiological changes, such as a reduction in liver...

    Chester Durnas, Cho-Ming Loi, Dr Barry J. Cusack in Clinical Pharmacokinetics (1990)

  6. No Access

    Chapter

    The Effects of Age on Hepatic Drug Metabolism

    Aging is a very complex process that is not completely understood. In the human life cycle, the growth-and-development phase ends near the age of 30 years and is followed by a gradual, often linear decline.1 Many...

    Cho-Ming Loi, Robert E. Vestal in Drug Studies in the Elderly (1986)